Benjamin Toll, PhD
Research & Publications
Biography
News
Research Summary
Dr. Toll conducts smoking cessation studies aimed at developing novel treatments (both counseling and drug treatments). He is currently testing treatments that emphasize the positive aspects of quitting smoking (e.g., quitting will add years to your life) and interventions aimed at reducing alcohol use amongst smokers who drink at hazardous levels. He is also conducting research aimed at improving the quality of measures of cigarette consumption (e.g., IVR) and smoking related syndromes (e.g., withdrawal).
Specialized Terms: Smoking cessation clinical trials; Quitline studies; Smoking cessation with cancer patients; Secondary analyses of clinical trial data; Analyses of mediators and moderators of treatment; Assessment, methods, and psychometrics
Extensive Research Description
- “Promoting Tobacco and Cancer Control: Message Framing for Telephone Quitline Callers” This project will be a secondary analysis of our New York State Smokers’ Quitline data.
- “Smoking Cessation to Improve Survival Rates of Head and Neck Cancer Patients” This project is an 8-week, open label clinical trial comparing smoking cessation treatment with varenicline 2 mg to nicotine patch 21 mg in a sample of 30 patients who completed treatment for head and neck cancer.
Coauthors
Research Interests
Psychiatry; Global Health; Smoking Cessation
Selected Publications
- Implementation of an “opt-out” tobacco treatment program in six hospitals in South CarolinaCummings K, Talbot V, Roberson A, Bliss A, Likins E, Brownstein N, Stansell S, Adams-Ludd D, Harris B, Louder D, McCutcheon E, Zebian R, Rojewski A, Toll B. Implementation of an “opt-out” tobacco treatment program in six hospitals in South Carolina. BMC Health Services Research 2024, 24: 741. PMID: 38886764, PMCID: PMC11184783, DOI: 10.1186/s12913-024-11205-7.
- Development of an Electronic Health Record Self-Referral Tool for Lung Cancer Screening: One-Group Posttest StudyStang G, Tanner N, Hatch A, Godbolt J, Toll B, Rojewski A. Development of an Electronic Health Record Self-Referral Tool for Lung Cancer Screening: One-Group Posttest Study. JMIR Formative Research 2024, 8: e53159. PMID: 38865702, DOI: 10.2196/53159.
- Barriers and facilitators to involvement in cancer education opportunities among South Carolina cancer care professionals: A cancer training and diversity, equity, and inclusion training needs assessmentHatch A, Shungu N, Ford M, Toll B. Barriers and facilitators to involvement in cancer education opportunities among South Carolina cancer care professionals: A cancer training and diversity, equity, and inclusion training needs assessment. Journal Of The National Medical Association 2024, 116: 283-291. PMID: 38816266, DOI: 10.1016/j.jnma.2024.05.001.
- Varenicline for E-Cigarette Cessation in Adults: A Preliminary Placebo-Controlled Randomized TrialFucito L, Baldassarri S, Baker N, Palmer A, O'Malley S, Carpenter M, Krishnan-Sarin S, Gray K, Toll B. Varenicline for E-Cigarette Cessation in Adults: A Preliminary Placebo-Controlled Randomized Trial. American Journal Of Preventive Medicine 2024 PMID: 38752949, DOI: 10.1016/j.amepre.2024.04.007.
- Nicotine e-cigarettes: considerations for healthcare providersToll B, Smith T, King B. Nicotine e-cigarettes: considerations for healthcare providers. Nature Medicine 2024, 1-2. PMID: 38627561, DOI: 10.1038/s41591-024-02926-7.
- Implementation, enrollment, and engagement in an opt‐out telehealth pharmacist‐assisted tobacco treatment program for patients seen in oncology outpatient clinicsCummings K, Toll B, Talbot V, Roberson A, Wilson D, Dunlap M, Ware E, Palmer A, Bliss A, Anokye V, Warren G. Implementation, enrollment, and engagement in an opt‐out telehealth pharmacist‐assisted tobacco treatment program for patients seen in oncology outpatient clinics. Cancer 2024 PMID: 38546445, DOI: 10.1002/cncr.35291.
- Abstract 4790: Hospitalization as an opportunity to improve lung cancer screening in high-risk patientsNielsen E, Zhang J, Marsden J, Bays C, Moran W, Mauldin P, Lenert L, Toll B, Schreiner A, Heincelman M. Abstract 4790: Hospitalization as an opportunity to improve lung cancer screening in high-risk patients. Cancer Research 2024, 84: 4790-4790. DOI: 10.1158/1538-7445.am2024-4790.
- Hospitalization as an opportunity to improve lung cancer screening in high-risk patientsNielsen E, Zhang J, Marsden J, Bays C, Moran W, Mauldin P, Lenert L, Toll B, Schreiner A, Heincelman M. Hospitalization as an opportunity to improve lung cancer screening in high-risk patients. Cancer Epidemiology 2024, 90: 102553. PMID: 38460398, DOI: 10.1016/j.canep.2024.102553.
- Shift From Smoking Cigarettes to Vaping Nicotine in Young AdultsSanford B, Brownstein N, Baker N, Palmer A, Smith T, Rojewski A, Toll B. Shift From Smoking Cigarettes to Vaping Nicotine in Young Adults. JAMA Internal Medicine 2024, 184: 106-108. PMID: 37955869, PMCID: PMC10644245, DOI: 10.1001/jamainternmed.2023.5239.
- Is hospitalization a missed opportunity to intervene on tobacco cessation?Nielsen E, Zhang J, Marsden J, Bays C, Moran W, Mauldin P, Lenert L, Toll B, Schreiner A, Heincelman M. Is hospitalization a missed opportunity to intervene on tobacco cessation? The American Journal Of The Medical Sciences 2023, 367: 89-94. PMID: 38043793, DOI: 10.1016/j.amjms.2023.11.024.
- Assessing Tobacco Use by Cancer Patients and Facilitating Cessation: An American Association for Cancer Research Policy StatementToll BA, Brandon TH, Gritz ER, Warren GW, Herbst RS, Tobacco and Cancer W. Assessing Tobacco Use by Cancer Patients and Facilitating Cessation: An American Association for Cancer Research Policy Statement. Clinical Cancer Research 2013, 19: 1941-1948. PMID: 23570694, PMCID: PMC5992896, DOI: 10.1158/1078-0432.ccr-13-0666.
- Tobacco Quitlines Need to Assess and Intervene with Callers' Hazardous DrinkingToll BA, Cummings KM, O'Malley SS, Carlin‐Menter S, McKee SA, Hyland A, Wu R, Hopkins J, Celestino P. Tobacco Quitlines Need to Assess and Intervene with Callers' Hazardous Drinking. Alcohol Clinical And Experimental Research 2012, 36: 1653-1658. PMID: 22703028, PMCID: PMC3436938, DOI: 10.1111/j.1530-0277.2012.01767.x.
- Low-dose naltrexone augmentation of nicotine replacement for smoking cessation with reduced weight gain: A randomized trialToll BA, White M, Wu R, Meandzija B, Jatlow P, Makuch R, O’Malley S. Low-dose naltrexone augmentation of nicotine replacement for smoking cessation with reduced weight gain: A randomized trial. Drug And Alcohol Dependence 2010, 111: 200-206. PMID: 20542391, PMCID: PMC3771701, DOI: 10.1016/j.drugalcdep.2010.04.015.
- Randomized Trial: Quitline Specialist Training in Gain-Framed vs Standard-Care Messages for Smoking CessationToll BA, Martino S, Latimer A, Salovey P, O'Malley S, Carlin-Menter S, Hopkins J, Wu R, Celestino P, Cummings KM. Randomized Trial: Quitline Specialist Training in Gain-Framed vs Standard-Care Messages for Smoking Cessation. Journal Of The National Cancer Institute 2010, 102: 96-106. PMID: 20056957, PMCID: PMC2808347, DOI: 10.1093/jnci/djp468.
- Comparing Gain- and Loss-Framed Messages for Smoking Cessation With Sustained-Release Bupropion: A Randomized Controlled TrialToll BA, O'Malley SS, Katulak NA, Wu R, Dubin JA, Latimer A, Meandzija B, George TP, Jatlow P, Cooney JL, Salovey P. Comparing Gain- and Loss-Framed Messages for Smoking Cessation With Sustained-Release Bupropion: A Randomized Controlled Trial. Psychology Of Addictive Behaviors 2007, 21: 534-544. PMID: 18072836, PMCID: PMC2527727, DOI: 10.1037/0893-164x.21.4.534.
- A preliminary investigation of naltrexone augmentation of bupropion to stop smoking with less weight gainToll BA, Leary V, Wu R, Salovey P, Meandzija B, O'Malley SS. A preliminary investigation of naltrexone augmentation of bupropion to stop smoking with less weight gain. Addictive Behaviors 2007, 33: 173-179. PMID: 17587504, PMCID: PMC2488403, DOI: 10.1016/j.addbeh.2007.05.012.